Cryoport Systems Now Supporting 7 Commercial Therapies Globally

Tue, Mar 30, 2021 | By Cryoport Team

We’re celebrating big news from two Cryoport Systems valued clients: bluebird bio and Bristol Myers-Squibb announced FDA approval of their cell therapy Abecma, a personalized immune therapy for patients with multiple myeloma. This also means Cryoport Systems is now supporting the distribution of seven commercial therapies globally: 

  • KYMRIAH® (Novartis) - Approved in the US, EU, Japan, and Singapore 
  • YESCARTA® (Gilead Sciences) - Approved in the US and EU 
  • Zynteglo® (bluebird bio) - Approved in the EU 
  • TECARTUS (Gilead Sciences) - Approved in the US 
  • Libmeldy™ (Orchard Therapeutics) - Approved in the EU 
  • BREYANZI® (Bristol Myers-Squibb) - Approved in the US and Japan 
  • Abecma® (bluebird bio and Bristol Myers-Squibb) - Approved in the US 

In addition to the above therapies, Cryoport Systems is providing the supply chain support for 528 cell and gene therapy clinical trials across the globe. The company’s acquisitions of CRYOPDP and MVE Biological Solutions in 2020 established a more robust and flexible global support network, enabling the company to reach more suppliers, trials and patients.  

More Updates 

 

Questions or comments? We welcome your feedback!

Email Us

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC